Peptide News Digest

#California

2 stories

Regulatory · View digest

Holt Law April Regulatory Alert: BPC-157 California Sherman Law Risk + Federal Pre-PCAC Compliance Reminders for Compounders

Holt Law's April update on BPC-157 reminded compounders and clinics that the FDA's Category 2 removal does not authorize compounding on its own — the seven-peptide PCAC meeting on July 23–24 is required first, followed by formal rulemaking. The alert flagged California-specific exposure: the state's Sherman Food, Drug and Cosmetic Law prohibits the sale or distribution of new drugs that have not received FDA or state approval, and prescribing or dispensing BPC-157 outside approved pathways could expose physicians to significant legal risks separate from federal enforcement. The piece complements the firm's January 2 critical-status alert and the broader 2026 state-by-state compounding-enforcement divergence between California (30+ Board of Pharmacy actions since 2023) and Texas (more permissive for licensed 503A operations).

Regulatory · View digest

State-Level Peptide Compounding Enforcement Diverges Sharply: California Board 30+ Actions Since 2023, Texas More Permissive for Licensed 503A Operations

FormBlends and the FDA Law Blog 'Pep(tide) Rally' analyses surfaced a state-level compliance map that compounders are now navigating ahead of the July PCAC. California's Board of Pharmacy has issued 30+ enforcement actions against peptide-compounding pharmacies since 2023, scrutinizing both quality and technical regulatory compliance. Texas Board of Pharmacy enforcement has historically focused on egregious quality violations rather than minor technical issues, making the state more accessible for licensed 503A and 503B operations under physician prescription. The gap matters because telehealth platforms route fulfillment through state-by-state pharmacy networks; a CVS or compounder routing decision in 2026 is now a state-policy decision as much as a federal one.